GlaxoSmithKline begins a phase III study of its new intravenous flu treatment ("zanamivir") that they hope will compete with competitor pill, Tamiflu.
This is intended to treat the sickest patients, who may not have responded to other treatments.
The pharmaceutical giant is hoping to take market share away from rival Roche.
http://www.reuters.com/article/idUSTRE70I1RU20110119
No comments:
Post a Comment